Effects of Simvastatin on Bone Turnover and BMD: A 1-Year Randomized Controlled Trial in Postmenopausal Osteopenic Women

Authors

  • Lars Rejnmark MD, PhD,

    Corresponding author
    1. Department of Endocrinology and Metabolism C, Aarhus Amtssygehus, Aarhus University Hospital, Aarhus, Denmark
    2. Faculty of Health Sciences, Aarhus University, Aarhus, Denmark
    • Department of Endocrinology and Metabolism C, Aarhus Amtssygehus, Aarhus University Hospital, Tage-Hansens Gade 2, DK-8000 Aarhus C, Denmark
    Search for more papers by this author
  • Henrik Niels Buus,

    1. Department of Endocrinology and Metabolism C, Aarhus Amtssygehus, Aarhus University Hospital, Aarhus, Denmark
    2. Centre for Clinical Pharmacology, Faculty of Health Sciences, Aarhus University, Aarhus, Denmark
    Search for more papers by this author
  • Peter Vestergaard,

    1. Department of Endocrinology and Metabolism C, Aarhus Amtssygehus, Aarhus University Hospital, Aarhus, Denmark
    2. Faculty of Health Sciences, Aarhus University, Aarhus, Denmark
    Search for more papers by this author
  • Lene Heickendorff,

    1. Department of Clinical Biochemistry, Aarhus Amtssygehus, Aarhus University Hospital, Aarhus, Denmark
    Search for more papers by this author
  • Frederik Andreasen,

    1. Centre for Clinical Pharmacology, Faculty of Health Sciences, Aarhus University, Aarhus, Denmark
    Search for more papers by this author
  • Lytken Mogens Larsen,

    1. Department of Medicine and Cardiology, Aarhus Amtssygehus, Aarhus University Hospital, Aarhus, Denmark
    Search for more papers by this author
  • Leif Mosekilde

    1. Department of Endocrinology and Metabolism C, Aarhus Amtssygehus, Aarhus University Hospital, Aarhus, Denmark
    2. Faculty of Health Sciences, Aarhus University, Aarhus, Denmark
    Search for more papers by this author

  • The authors have no conflict of interest.

Abstract

To study effects of statins on human bone, 82 postmenopausal women were randomized to 1-year treatment with simvastatin 40 mg/day or placebo. The study showed no effect of simvastatin on biochemical bone markers or on BMD at the hip or spine. Thus, our results do not support a general beneficial effect of simvastatin on bone.

Introduction: Statins have been reported to cause bone anabolic as well as antiresorptive effects, and therefore statins have been suggested as potential agents in treatment of osteoporosis.

Materials and Methods: In a double-blinded design, 82 healthy postmenopausal women with osteopenia were randomized to 1-year simvastatin treatment 40 mg/day or placebo. BMD and plasma levels of cholesterol, parathyroid hormone (PTH), and biochemical bone markers were measured at baseline, after 1 year of treatment (week 52), and 26 weeks after withdrawal of treatment (week 78). Calcium supplements (400 mg/day) were administrated during the entire 1.5-year study period.

Results: Seventy-eight women completed the 1-year treatment. After 1 year, simvastatin but not placebo caused reduced plasma cholesterol (−27% versus +1%, p < 0.001) and low-density lipoprotein (LDL) levels (−43% versus +1%, p < 0.001). After withdrawal of treatment, cholesterol and LDL levels returned to baseline levels and no longer differed from the placebo group. However, plasma levels of PTH and biochemical bone markers did not differ between groups at week 52 or 78. Compared with placebo, simvastatin caused no changes in BMD at the lumbar spine, total hip, femoral neck, or whole body at week 52 or 78. However, a significant increase in BMD was found in response to simvastatin at the forearm. Within the simvastatin group, changes in cholesterol levels did not correlate to BMD changes at any site.

Conclusions: Our results do not support a general beneficial effect of simvastatin on bone.

Ancillary